- Home
- SWI vs ACAD Comparison
SWI vs ACAD Comparison
Compare SWI & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SWI
- ACAD
- Stock Information
- Founded
- SWI 1999
- ACAD 1993
- Country
- SWI United States
- ACAD United States
- Employees
- SWI N/A
- ACAD N/A
- Industry
- SWI Computer Software: Prepackaged Software
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- SWI Technology
- ACAD Health Care
- Exchange
- SWI Nasdaq
- ACAD Nasdaq
- Market Cap
- SWI 2.5B
- ACAD 2.9B
- IPO Year
- SWI 2009
- ACAD 2004
- Fundamental
- Price
- SWI $14.45
- ACAD $16.68
- Analyst Decision
- SWI Hold
- ACAD Buy
- Analyst Count
- SWI 7
- ACAD 18
- Target Price
- SWI $14.71
- ACAD $26.53
- AVG Volume (30 Days)
- SWI 688.2K
- ACAD 1.7M
- Earning Date
- SWI 02-06-2025
- ACAD 11-06-2024
- Dividend Yield
- SWI N/A
- ACAD N/A
- EPS Growth
- SWI N/A
- ACAD N/A
- EPS
- SWI 0.22
- ACAD 0.78
- Revenue
- SWI $784,725,000.00
- ACAD $929,236,000.00
- Revenue This Year
- SWI $5.08
- ACAD $37.34
- Revenue Next Year
- SWI $3.04
- ACAD $7.25
- P/E Ratio
- SWI $64.94
- ACAD $21.73
- Revenue Growth
- SWI 4.96
- ACAD 47.06
- 52 Week Low
- SWI $10.14
- ACAD $14.15
- 52 Week High
- SWI $14.94
- ACAD $32.59
- Technical
- Relative Strength Index (RSI)
- SWI 58.03
- ACAD 48.24
- Support Level
- SWI $13.76
- ACAD $16.27
- Resistance Level
- SWI $14.94
- ACAD $17.86
- Average True Range (ATR)
- SWI 0.46
- ACAD 0.78
- MACD
- SWI -0.04
- ACAD -0.13
- Stochastic Oscillator
- SWI 66.21
- ACAD 20.62
About SWI SolarWinds Corporation
SolarWinds Corp is a provider of information technology (IT), and management software. Company offers full-stack observability solutions. The company's business is focused on building products that enable technology professionals and leaders to securely monitor and manage the performance of their IT environments, whether on-premises, in the cloud or in hybrid deployments. The products offered are designed to monitor and manage networks, systems, databases and applications across on-premises, multi-cloud and hybrid IT environments without the need for customization or professional services.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecules drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.